Arctigenin Anti-Tumor Activity in Bladder Cancer T24 Cell Line Through Induction of Cell-Cycle Arrest and Apoptosis

Anatomical Record

Volumn 295, Issue 8, 2012, Pages 1260-1266

  Yang, Shucai ^a   Ma, Jing ^a   Xiao, Jianbing ^a   Lv, Xiaohong ^a   Li, Xinlei ^a   Yang, Huike ^a   Liu, Ying ^a   Feng, Sijia ^a   Zhang, Yafang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arctigenin; Bladder cancer; CyclinD1; ERK1 2; P38

Indexed keywords

ARCTIGENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FLOW CYTOMETRY; FURANS; HUMANS; LIGNANS; MITOGEN-ACTIVATED PROTEIN KINASES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84863549883     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22497     Document Type: Article

References (32)

1. Adams RR, Maiato H, Earnshaw WC, Carmena M. 2001. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 153: 865- 880.
2. Ashughyan VR, Marihart S, Djavan B. 2006. Chemopreventive trials in urologic cancer. Rev Urol 8: 8- 13.
3. Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S, Esumi H. 2006. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66: 1751- 1757.
4. Bushy JE, Kamat AM. 2006. Chemoprevention for bladder cancer. J Urol 176: 1914- 1920.
5. Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. 1997. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 90: 315- 323.
6. Cho JY, Kim AR, Yoo ES, Baik KU, Park MH. 1999. Immunomodulatory effect of arctigenin, a lignan compound on tumor necrosis factor-alpha and nitric oxide production, and lymphocyte proliferation. J Pharm Pharmacol 51: 1267- 1273.
7. Cho MK, Jang YP, Kim YC, Kim SG. 2004. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. Int Immunopharmacol 4: 1419- 1429.
8. Dammai V, Hsu T. 2003. EGF-dependent and independent activation of MAP kinase during Drosophila oogenesis. Anat Rec A Discov Mol Cell Evol Biol 272: 377- 382.
9. Hausott B, Greger HM, Marian B. 2003. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol 129: 569- 576.
10. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC. 2003. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101: 703- 705.
11. Hideshima T, Anderson KC. 2002. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927- 937.
12. Hirose M, Yamaguchi T, Lin C, Kimoto N, Futakuchi M, Kono T, Nishibe S, Shirai T. 2000. Effects of arctiin on PhIP-induced mammary, colon and pancreatic carcinogensis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats. Cancer Lett 155: 79- 88.
13. Huang DM, Guh JH, Chueh SC, Teng CM. 2004. Modulation of anti-adhesion molecule MUC-1 is associated with arctiin-induced growth inhibition in PC-3 cells. Prostate 59: 260- 267.
14. Huang TC, Tsai SS, Liu LF, Liu YL, Liu HJ, Chuang KP. 2010. Effect of Arctium lappa L. in the dextran sulfate sodium colitis mouse model. World J Gastroenterol 16: 4193- 4199.
15. Jacks T, Weinberg RA. 1996. Cell-cycle control and its watchman. Nature 381: 643- 644.
16. Jernal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. 2004. Cancer statistics, 2004. CA Cancer J Clin 54: 8- 29.
17. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by Erk, JNK, and p38 protein kinases. Science 298: 1911- 1912.
18. Kamat AM, Lamm DL. 2002. Chemoprevention of bladder cancer. Urol Clin North Am 29: 157- 168.
19. Knowlton AL, Lan W, Stukenberg PT. 2006. Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol 16: 1705- 1710.
20. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldeqrun AS, Pantuck AJ. 2006. Prevention of bladder cancer: a review. Eur Urol 49: 226- 234.
21. Lin CC, Lu JM, Yang JJ, Chuang SC, Ujiie T. 1996. Anti-inflammatory and radical scavenge effects of Arctium lappa. Am J Chin Med 24: 127- 137.
22. Malumbres M, Hunt SL, Sotillo R, Martín J, Odajima J, Martín A, Dubus P, Ortega S, Barbacid M. 2003. Driving the cell cycle to cancer. Adv Exp Med Biol 532: 1- 11. 12908544]
23. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN. 2008. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68: 2599- 2609.
24. Saeki T, Ouchi M, Ouchi T. 2009. Physiological and oncogenic Aurora-A pathway. Int J Biol Sci 5: 758- 762.
25. Santamaria D, Ortega S. 2006. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 11: 1164- 1188.
26. Sherr CJ. 1996. Cancer cell cycles. Science 274: 1672- 1677.
27. Sherr CJ, Robert JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501- 1512.
28. Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y, Kizaki M. 2006. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol 71: 742- 750.
29. Söderström TS, Poukkula M, Holmström TH, Heiskanen KM, Eriksson JE. 2002. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol 169: 2851- 2860.
30. Song G, Ouyang G, Bao S. 2005. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59- 71.
31. Takasaki M, Konoshima T, Komatsu K, Tokuda H, Nishino H. 2000. Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa. Cancer Lett 158: 53- 59.
32. Yan S, Wenner CE. 2001. Modulation of cyclin D1 and its signaling components by the phorbol ester TPA and the tyrosine phosphatase inhibitor vanadate. J Cell Physiol 186: 338- 349.